SEMA4D and plasma cell myeloma: (2) Terpos et al. (2) reported increased soluble Sema4D in serum and bone marrow plasma of patients with myeloma, a bone marrow cancer with uncoupled osteoclast activation and osteoblast suppression, compared to controls.